Veracyte, Inc. (VCYT)

NGM – Real vaqt narxi. Valyuta: USD

60.49

+1.94 (3.31%)

Yopilishda: Jun 26, 2026, 4:00 PM EDT

60.37

-0.12 (-0.20%)

Bozordan keyin: Jun 26, 2026, 7:58 PM EDT

11.06.2026

Why Veracyte (VCYT) is a Top Momentum Stock for the Long-Term

The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.

09.06.2026

Here's Why Veracyte (VCYT) is a Strong Growth Stock

The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.

04.06.2026

Why Is Veracyte (VCYT) Up 18.2% Since Last Earnings Report?

Veracyte (VCYT) reported earnings 30 days ago. What's next for the stock?

01.06.2026

Veracyte, Inc. (VCYT) Discusses ASCO Findings From OPTIMA and ENZAMET Phase III Trials in Breast and Prostate Cancer Transcript

01.06.2026

Veracyte Announces Commercial Launch of the Prosigna Breast Test in the U.S.

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)---- $VCYT #BreastCancer--Veracyte Announces Commercial Launch of the Prosigna Breast Test in the U.S.

30.05.2026

ENZAMET Trial Shows Veracyte's Decipher Prostate Test Identifies Which Patients Benefit from Adding Chemotherapy in Metastatic Prostate Cancer

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)---- $VCYT #ASCO26--ENZAMET Trial Shows Veracyte's Decipher Prostate Test Identifies Which Patients Benefit from Adding Chemotherapy in Metastatic Prostate Cancer.

29.05.2026

Landmark OPTIMA Trial Delivers Practice-Changing Evidence that Veracyte's Prosigna Test Identifies Patients with High-Risk Breast Cancer Who Can Safely Avoid Chemotherapy

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)---- $VCYT #ASCO26--OPTIMA Trial Delivers Practice-Changing Evidence that Prosigna Test Identifies Patients with High-Risk Breast Cancer Who Can Safely Avoid Chemo.

Videolar

No Data

There is no data to display

Press-relizlar

01.06.2026

Veracyte Announces Commercial Launch of the Prosigna Breast Test in the U.S.

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)---- $VCYT #BreastCancer--Veracyte Announces Commercial Launch of the Prosigna Breast Test in the U.S.

30.05.2026

ENZAMET Trial Shows Veracyte's Decipher Prostate Test Identifies Which Patients Benefit from Adding Chemotherapy in Metastatic Prostate Cancer

29.05.2026

Landmark OPTIMA Trial Delivers Practice-Changing Evidence that Veracyte's Prosigna Test Identifies Patients with High-Risk Breast Cancer Who Can Safely Avoid Chemotherapy

22.05.2026

Veracyte to Host Investor Call on June 1, 2026 to Discuss ASCO Findings

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Veracyte, Inc. (Nasdaq: VCYT), a leading cancer diagnostics company, today announced that it will host a conference call and webcast on Monday, June 1, 2026 at 8:30 a.m. ET to discuss data from two significant phase III clinical trials using its Prosigna Breast and Decipher Prostate tests that will be presented at the 2026 ASCO Annual Meeting. This includes results from the OPTIMA and ENZAMET trials. Professor Iain Macpherson, one of the principal i.

Veracyte, Inc. (VCYT)

Aksiya tahlili uchun eng kuchli vositalarga ega bo'ling

Finranks

Kompaniya

Biz bilan bog'lanish

Bizni kuzating

Veracyte, Inc. (VCYT)

Why Veracyte (VCYT) is a Top Momentum Stock for the Long-Term

Here's Why Veracyte (VCYT) is a Strong Growth Stock

Why Is Veracyte (VCYT) Up 18.2% Since Last Earnings Report?

Veracyte, Inc. (VCYT) Discusses ASCO Findings From OPTIMA and ENZAMET Phase III Trials in Breast and Prostate Cancer Transcript

Veracyte Announces Commercial Launch of the Prosigna Breast Test in the U.S.

ENZAMET Trial Shows Veracyte's Decipher Prostate Test Identifies Which Patients Benefit from Adding Chemotherapy in Metastatic Prostate Cancer

Landmark OPTIMA Trial Delivers Practice-Changing Evidence that Veracyte's Prosigna Test Identifies Patients with High-Risk Breast Cancer Who Can Safely Avoid Chemotherapy

Videolar

No Data

Press-relizlar

Veracyte Announces Commercial Launch of the Prosigna Breast Test in the U.S.

ENZAMET Trial Shows Veracyte's Decipher Prostate Test Identifies Which Patients Benefit from Adding Chemotherapy in Metastatic Prostate Cancer

Landmark OPTIMA Trial Delivers Practice-Changing Evidence that Veracyte's Prosigna Test Identifies Patients with High-Risk Breast Cancer Who Can Safely Avoid Chemotherapy

Veracyte to Host Investor Call on June 1, 2026 to Discuss ASCO Findings

Why Veracyte (VCYT) is a Top Momentum Stock for the Long-Term

Here's Why Veracyte (VCYT) is a Strong Growth Stock

Why Is Veracyte (VCYT) Up 18.2% Since Last Earnings Report?

Veracyte, Inc. (VCYT) Discusses ASCO Findings From OPTIMA and ENZAMET Phase III Trials in Breast and Prostate Cancer Transcript

Veracyte Announces Commercial Launch of the Prosigna Breast Test in the U.S.

ENZAMET Trial Shows Veracyte's Decipher Prostate Test Identifies Which Patients Benefit from Adding Chemotherapy in Metastatic Prostate Cancer

Landmark OPTIMA Trial Delivers Practice-Changing Evidence that Veracyte's Prosigna Test Identifies Patients with High-Risk Breast Cancer Who Can Safely Avoid Chemotherapy

Videolar

No Data

Press-relizlar

Veracyte Announces Commercial Launch of the Prosigna Breast Test in the U.S.

ENZAMET Trial Shows Veracyte's Decipher Prostate Test Identifies Which Patients Benefit from Adding Chemotherapy in Metastatic Prostate Cancer

Landmark OPTIMA Trial Delivers Practice-Changing Evidence that Veracyte's Prosigna Test Identifies Patients with High-Risk Breast Cancer Who Can Safely Avoid Chemotherapy

Veracyte to Host Investor Call on June 1, 2026 to Discuss ASCO Findings

Search stocks

Veracyte, Inc. (VCYT)

Aksiya tahlili uchun eng kuchli vositalarga ega bo'ling

Finranks

Kompaniya

Biz bilan bog'lanish

Bizni kuzating

Veracyte, Inc. (VCYT)

Why Veracyte (VCYT) is a Top Momentum Stock for the Long-Term

Here's Why Veracyte (VCYT) is a Strong Growth Stock

Why Is Veracyte (VCYT) Up 18.2% Since Last Earnings Report?

Veracyte, Inc. (VCYT) Discusses ASCO Findings From OPTIMA and ENZAMET Phase III Trials in Breast and Prostate Cancer Transcript

Veracyte Announces Commercial Launch of the Prosigna Breast Test in the U.S.

ENZAMET Trial Shows Veracyte's Decipher Prostate Test Identifies Which Patients Benefit from Adding Chemotherapy in Metastatic Prostate Cancer

Landmark OPTIMA Trial Delivers Practice-Changing Evidence that Veracyte's Prosigna Test Identifies Patients with High-Risk Breast Cancer Who Can Safely Avoid Chemotherapy

Videolar

No Data

Press-relizlar

Veracyte Announces Commercial Launch of the Prosigna Breast Test in the U.S.

ENZAMET Trial Shows Veracyte's Decipher Prostate Test Identifies Which Patients Benefit from Adding Chemotherapy in Metastatic Prostate Cancer

Landmark OPTIMA Trial Delivers Practice-Changing Evidence that Veracyte's Prosigna Test Identifies Patients with High-Risk Breast Cancer Who Can Safely Avoid Chemotherapy

Veracyte to Host Investor Call on June 1, 2026 to Discuss ASCO Findings

Why Veracyte (VCYT) is a Top Momentum Stock for the Long-Term

Here's Why Veracyte (VCYT) is a Strong Growth Stock

Why Is Veracyte (VCYT) Up 18.2% Since Last Earnings Report?

Veracyte, Inc. (VCYT) Discusses ASCO Findings From OPTIMA and ENZAMET Phase III Trials in Breast and Prostate Cancer Transcript

Veracyte Announces Commercial Launch of the Prosigna Breast Test in the U.S.

ENZAMET Trial Shows Veracyte's Decipher Prostate Test Identifies Which Patients Benefit from Adding Chemotherapy in Metastatic Prostate Cancer

Landmark OPTIMA Trial Delivers Practice-Changing Evidence that Veracyte's Prosigna Test Identifies Patients with High-Risk Breast Cancer Who Can Safely Avoid Chemotherapy

Videolar

No Data

Press-relizlar

Veracyte Announces Commercial Launch of the Prosigna Breast Test in the U.S.

ENZAMET Trial Shows Veracyte's Decipher Prostate Test Identifies Which Patients Benefit from Adding Chemotherapy in Metastatic Prostate Cancer

Landmark OPTIMA Trial Delivers Practice-Changing Evidence that Veracyte's Prosigna Test Identifies Patients with High-Risk Breast Cancer Who Can Safely Avoid Chemotherapy

Veracyte to Host Investor Call on June 1, 2026 to Discuss ASCO Findings